Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH

Remschmidt, Helmut; Hoare, Peter; Ettrich, Christine; Rothenberger, Aribert; Santosh, Paramala; Schmidt, Martin H.; Spender, Quentin; Tamhne, R.; Thompson, Margaret; Tinline, C.; Trott, Götz‐Erik; Medori, Rossella

doi:10.1007/s00787-005-0467-6

Cited by 29 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparing the two studies by Hoare et al and Remschmidt et al (12 months vs 3 weeks), a similar incidence of abdominal pain (4% in both studies) and headache (10% vs 8%) was reported, while the incidence of tics doubled (8% vs 4%) 23 36…”

Section: Resultssupporting

confidence: 54%

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Clavenna

Bonati

2014

Archives of Disease in Childhood

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 54%

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Clavenna

Bonati

2014

Archives of Disease in Childhood

View full text Add to dashboard Cite

show abstract

“…A small number of studies have compared extended-release and immediate-release methylphenidate, including two that showed that switching from immediate-release to extended-release methylphenidate improved symptom control in children and adolescents with ADHD 44,45. There was also an improvement in compliance after the switch in one of these studies;44 no data on compliance were provided in the published results from the other study 45. In addition, a study of children with ADHD who were poorly compliant with immediate-release methylphenidate showed that, after switching to extended-release methylphenidate, 72% of children had good compliance 46.…”

Section: Discussionmentioning

confidence: 99%

The role of galenic innovation in improving treatment compliance and persistence: three case studies

Zoellner¹,

Balp²,

Marco³

2011

CEOR

View full text Add to dashboard Cite

Background:The purpose of this study was to explore whether newer galenic formulations with lower treatment burdens are associated with better patient compliance and persistence compared with older more burdensome modalities.Methods:Data from the IMS Disease Analyzer database were analyzed retrospectively for two pairs of analogs (alendronate sodium once daily vs once weekly and immediate-release vs extended-release methylphenidate) and one pair of drugs with similar indications but important differences in convenience and dosing instructions (desferrioxamine vs deferasirox). Compliance was calculated as the sum of prescription durations for all prescriptions for each patient over 1 year. Persistence was calculated as the time between first and last prescriptions over 2 years (1 year for deferasirox and desferrioxamine). Data from Germany and the UK were available and used for analysis.Results:Incremental improvements in compliance were +30% in the UK and +26% in Germany for alendronate once weekly vs once daily, +14% in the UK and +19% in Germany for extended-release vs immediate-release methylphenidate, and +15% in Germany for desferrioxamine vs deferasirox. Incremental improvements in persistence were +9 months in the UK and +8 months in Germany for alendronate once weekly vs once daily, +4 months in the UK and +3 months in Germany for extended-release vs immediate-release methylphenidate, and +2 months in Germany for deferasirox vs desferrioxamine.Conclusion:The new formulations that we evaluated were associated with better compliance and persistence compared with older formulations. Despite the fact that some sources of bias could not be excluded, it is likely that these improvements can be attributed to the lower treatment burdens of the galenic formulations of the drugs considered. Further investigation is required to confirm these findings and to determine whether new galenic formulations can improve health outcomes in routine clinical practice.

show abstract

“…More recently, a prospective cross-over study of 30 children also demonstrated that ER MPH formulations (Ritalin LA, OROS MPH) provided an improvement for patients, which is in keeping with Ritalin IR efficacy through once-daily administration [29]. However, a 1-month switching study (from IR MPH to OROS MPH) indicated that, unlike IR MPH, OROS MPH improved symptom control in the after-school period [84]. However, it is important to note that this was an open-label, non-randomized, dose-adjustment study and the extent to which raters may have been biased by their knowledge of medication cannot be assessed [84].…”

Section: Targets Of Therapy and The Potential Advantages Of Extendingmentioning

confidence: 93%

“…However, a 1-month switching study (from IR MPH to OROS MPH) indicated that, unlike IR MPH, OROS MPH improved symptom control in the after-school period [84]. However, it is important to note that this was an open-label, non-randomized, dose-adjustment study and the extent to which raters may have been biased by their knowledge of medication cannot be assessed [84]. Similarly, results from a prospective study demonstrated that OROS MPH was effective during the late afternoon and homework time, and consistent with parents’ preference, was finally prescribed in over twice as many children as Ritalin LA [29].…”

Section: Targets Of Therapy and The Potential Advantages Of Extendingmentioning

confidence: 99%

Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants

Buitelaar

Medori²

2009

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD), one of the most common neuropsychiatric conditions of childhood, often has a chronic course and persists into adulthood in many individuals. ADHD may have a clinically important impact on health-related quality of life in children, a significant impact on parents’ emotional health and interfere with family activities/cohesion. To date, the main targets of ADHD treatment have focused on reducing the severity of symptoms during the school day and improving academic performance. However, the treatment of ADHD should reach beyond symptom control to address the issues of social competencies and improvement of health-related quality of life from the perspectives of individuals with ADHD and their families, to support them in reaching their full developmental potential. Methylphenidate (MPH) is recognised as the first-line choice of pharmacotherapy for ADHD in children and adolescents. This paper focuses on the importance and benefits to child development of ADHD symptom control beyond the school day only, i.e. extending into late afternoon and evening and uses the example of an extended-release MPH formulation (OROS® MPH) to demonstrate the potential benefits of active full day coverage (12 h) with a single daily dose. Concerns of long-term stimulant treatment are also discussed.

show abstract

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH

Cited by 29 publications

References 12 publications

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

The role of galenic innovation in improving treatment compliance and persistence: three case studies

Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants

Contact Info

Product

Resources

About